Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update

Foghorn posts a one-time revenue surge but pipeline milestones remain years away.

What the company is saying

Foghorn Therapeutics, led by CEO Adrian Gottschalk, frames the update around strong financial results and progress in its preclinical pipeline. The company emphasizes an $83.5 million collaboration revenue figure for Q3 2026, up from $8.2 million a year earlier, attributing the $75.4 million increase mainly to a $74.1 million cumulative catch-up adjustment after discontinuing FHD-909 and the SMARCA2 selective degrader. Management highlights a net income of $58.2 million for the quarter, reversing a $15.8 million loss in Q3 2025, and points to a cash position of $156.2 million, projecting runway into the second half of 2029. The narrative stresses pipeline advancement, including a novel oral I&I program in IBD with dose-range finding studies set for late 2026 and possible first-in-human trials by end-2027, and a Selective EP300 degrader with an IND targeted for 2027. The company also promotes its ERIP induced-proximity platform as a future differentiator. While the tone is confident and forward-looking, the operational claims rest on preclinical models without quantitative efficacy data.

What the data suggests

The financials show a dramatic year-over-year improvement, with collaboration revenue jumping to $83.5 million in Q3 2026 from $8.2 million in Q3 2025. This increase is almost entirely due to a $74.1 million catch-up adjustment tied to the decision not to advance two programs, not to recurring business growth. Research and development expenses declined to $18.8 million from $20.0 million, and general and administrative expenses fell to $5.8 million from $6.7 million, reflecting cost control. Net income swung positive to $58.2 million from a $15.8 million loss a year ago, but this is not expected to repeat absent further one-time items. Cash, cash equivalents, and marketable securities stood at $156.2 million as of September 30, 2026, supporting the claim of a cash runway into 2029. Deferred revenue was $146.3 million, with total assets of $190.95 million and liabilities of $205.04 million, resulting in a stockholders’ deficit of $14.08 million. The pipeline remains preclinical, with no disclosed quantitative efficacy or safety data for the I&I or EP300 programs, and timelines for clinical entry extend into late 2027.

Analysis

The announcement presents a positive tone, highlighting both financial improvement and pipeline progress. Financial results are well-supported, with clear disclosure of revenue, expenses, net income, and cash position. However, the narrative around the pipeline is forward-looking: key programs (oral I&I in IBD, Selective EP300 degrader, ERIP) are described as advancing, but all efficacy claims are based on preclinical models with no quantitative data provided. The most significant pipeline milestones (dose-range finding studies, IND filings, first-in-human trials) are not expected until late 2026 or 2027, placing any clinical or commercial benefit well into the future. The large increase in revenue is a one-time accounting adjustment, not recurring operational growth. While the company is not currently disclosing a large capital outlay, the long timelines and lack of clinical data mean the narrative somewhat overstates near-term value creation.

Risk flags

• ●The surge in revenue and net income is driven by a one-time $74.1 million accounting adjustment, not by sustainable operational growth, so future quarters may not repeat these results.
• ●The company’s pipeline is entirely preclinical, with no quantitative efficacy or safety data disclosed for its lead programs, increasing the risk that future clinical trials may not deliver the expected outcomes.
• ●Major pipeline milestones, including first-in-human trials, are at least a year away, exposing the company to development, regulatory, and competitive risks over a long execution window.
• ●Despite a strong cash position of $156.2 million and projected runway into 2029, the company carries a stockholders’ deficit of $14.08 million and total liabilities exceeding total assets, which could constrain future financing or partnership options if pipeline progress stalls.
• ●Claims of superior efficacy and safety for the EP300 degrader and robust suppression in the I&I program are not supported by disclosed quantitative data, making it difficult for investors to independently assess the scientific merit.

Bottom line

Foghorn’s Q3 2026 update is dominated by a one-time revenue boost from a catch-up adjustment, not by recurring business growth or product sales. The company’s cash position is solid at $156.2 million, providing several years of operational runway, but its lead programs remain preclinical with no quantitative data disclosed to support claims of efficacy or safety. Key clinical milestones are not expected until late 2027 at the earliest, so near-term catalysts are limited. The operational narrative is credible on financials but aspirational on pipeline progress, with significant execution and data-readout risks ahead. Investors should focus on the transition from preclinical to clinical development and look for future updates that include hard efficacy and safety data. The most important takeaway is that while the balance sheet is stable for now, sustainable value creation depends on delivering clinical results that are still years away.

Announcement summary

(NASDAQ:FHTX) Foghorn Therapeutics Inc. provided a financial and corporate update in conjunction with its 10-Q filing for the third quarter ended September 30, 2026. Adrian Gottschalk, President and Chief Executive Officer, stated the company is focused on advancing its wholly owned portfolio, including a novel, oral immunology and inflammation (I&I) program in inflammatory bowel disease (IBD), with potential for first-in-human trials by the end of 2027, and a Selective EP300 degrader with an IND targeted for 2027. The company is also progressing a novel induced-proximity approach (ERIP) to degrade secreted and transmembrane proteins, aiming for antibody-like efficacy through small molecules. Preclinical data for the oral I&I program showed robust suppression of disease activity in T-cell transfer colitis and IL-10 knock-out models, with efficacy comparable to an anti-IL-12/23p40 antibody positive control. Dose-range finding studies for this program are expected to begin in the fourth quarter of 2026. The Selective EP300 degrader program demonstrated superior anti-tumor activity and safety in preclinical models, including complete responses in multiple myeloma (MM) and tumor regression in a xenograft model of acquired pomalidomide resistance, outperforming the clinical benchmark dual CBP/EP300 inhibitor inobrodib. Collaboration revenue for the three months ended September 30, 2026, was $83.5 million, compared to $8.2 million for the same period in 2025, with the $75.4 million increase driven by a $74.1 million cumulative catch-up adjustment related to updated estimated future costs for the decision not to advance FHD-909 and the SMARCA2 selective degrader. Research and development expenses were $18.8 million for the quarter, down from $20.0 million in the prior year, primarily due to decreased Lilly-partnered program costs, facilities, IT, and personnel-related expenses, partially offset by increased early development and external costs. General and administrative expenses were $5.8 million, compared to $6.7 million in the prior year, with the $0.9 million decrease attributed to lower personnel, professional, consulting, facilities, and IT-related costs. Net income for the quarter was $58.2 million, compared to a net loss of $15.8 million for the same period in 2025. As of September 30, 2026, Foghorn had $156.2 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2029. Deferred revenue as of September 30, 2026, was $146.3 million, and total assets were $191.0 million. Total liabilities were $205.0 million, and total stockholders’ deficit was $14.1 million. Weighted average common shares outstanding—basic for the quarter were 71,460,569, and diluted were 72,590,923. Net income per share attributable to common stockholders was $0.81 basic and $0.80 diluted for the quarter.

Disagree with this article?